Heterologous ChAdOx1-S/BNT162b2 Vaccination: Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Dear Editor,A recent report questioned whether one vaccine was better than another and how to evaluate this difference, but only homologous vaccination schedules were considered. Concern about the safety of the ChAdOx1-S vaccine have prompted some European countries to recommend using a heterologous...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2022-04, Vol.74 (7), p.1315-1316 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1316 |
|---|---|
| container_issue | 7 |
| container_start_page | 1315 |
| container_title | Clinical infectious diseases |
| container_volume | 74 |
| creator | Dimeglio, Chloé Herin, Fabrice Da-Silva, Isabelle Jougla, Isabelle Pradere, Claire Porcheron, Marion Martin-Blondel, Guillaume Chapuy-Regaud, Sabine Izopet, Jacques |
| description | Dear Editor,A recent report questioned whether one vaccine was better than another and how to evaluate this difference, but only homologous vaccination schedules were considered. Concern about the safety of the ChAdOx1-S vaccine have prompted some European countries to recommend using a heterologous booster, as proposed for mRNA vaccines for people under 55 years old . Immunogenicity and reactogenicity of a BNT162b2 booster in ChAdOx1-S-primed subjects was assessed in a multicenter, open-label, randomised, controled phase 2 trial, but included no homologous vaccination comparator. Few studies have compared the immune responses to homologous and heterologous vaccinationschedules in humans. |
| doi_str_mv | 10.1093/cid/ciab705 |
| format | Article |
| fullrecord | <record><control><sourceid>oup_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03682415v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/cid/ciab705</oup_id><sourcerecordid>10.1093/cid/ciab705</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-d0961b260c43368296d54dc6f5195af26cc02e9b32ae54806e5402a300cd72fb3</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EorxW7JFXCIRCx3bsJuxCBBSpohKBbiPHdopRG1dOUlF-gZ8mpdAli3lo5swd6SJ0SuCaQMz6yuouZDEAvoMOCGeDQPCY7HY98CgIIxb10GFdvwMQEgHfRz0WsojFQA_Q19A0xruZm7q2xulboscfJMj6t08vRNCC4olUylaysa66wU-mbbyc2U9bTXFSNbZweoWfTb1wVW1w43BmlsYbnKi2MT8L62Xj_Apnq0p7Nzc4dd5Vcml994_iiyx5zoLUTQJ6eYz2SjmrzclvPUKv93cv6TAYjR8e02QUKBaTJtAQC1JQASpkTEQ0FpqHWomSk5jLkgqlgJq4YFQaHkYgugxUMgClB7Qs2BG63Oi-yVm-8HYu_Sp30ubDZJSvZ7CWDQlfko692rDKu7r2ptweEMjX9ued_fmv_R19tqEXbTE3esv--d0B5xvAtYt_lb4BKQuM3g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Heterologous ChAdOx1-S/BNT162b2 Vaccination: Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Dimeglio, Chloé ; Herin, Fabrice ; Da-Silva, Isabelle ; Jougla, Isabelle ; Pradere, Claire ; Porcheron, Marion ; Martin-Blondel, Guillaume ; Chapuy-Regaud, Sabine ; Izopet, Jacques</creator><creatorcontrib>Dimeglio, Chloé ; Herin, Fabrice ; Da-Silva, Isabelle ; Jougla, Isabelle ; Pradere, Claire ; Porcheron, Marion ; Martin-Blondel, Guillaume ; Chapuy-Regaud, Sabine ; Izopet, Jacques</creatorcontrib><description>Dear Editor,A recent report questioned whether one vaccine was better than another and how to evaluate this difference, but only homologous vaccination schedules were considered. Concern about the safety of the ChAdOx1-S vaccine have prompted some European countries to recommend using a heterologous booster, as proposed for mRNA vaccines for people under 55 years old . Immunogenicity and reactogenicity of a BNT162b2 booster in ChAdOx1-S-primed subjects was assessed in a multicenter, open-label, randomised, controled phase 2 trial, but included no homologous vaccination comparator. Few studies have compared the immune responses to homologous and heterologous vaccinationschedules in humans.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/ciab705</identifier><identifier>PMID: 34383902</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Antibodies, Neutralizing ; Antibodies, Viral ; BNT162 Vaccine ; COVID-19 - prevention & control ; Humans ; Immunology ; Life Sciences ; SARS-CoV-2 ; Vaccination ; Vaccinology</subject><ispartof>Clinical infectious diseases, 2022-04, Vol.74 (7), p.1315-1316</ispartof><rights>The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. 2021</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-d0961b260c43368296d54dc6f5195af26cc02e9b32ae54806e5402a300cd72fb3</citedby><cites>FETCH-LOGICAL-c391t-d0961b260c43368296d54dc6f5195af26cc02e9b32ae54806e5402a300cd72fb3</cites><orcidid>0000-0002-3713-4913 ; 0000-0003-0689-7608 ; 0000-0002-8462-3234 ; 0000-0002-8363-7028 ; 0000-0001-6020-2083</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,1584,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34383902$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://ut3-toulouseinp.hal.science/hal-03682415$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Dimeglio, Chloé</creatorcontrib><creatorcontrib>Herin, Fabrice</creatorcontrib><creatorcontrib>Da-Silva, Isabelle</creatorcontrib><creatorcontrib>Jougla, Isabelle</creatorcontrib><creatorcontrib>Pradere, Claire</creatorcontrib><creatorcontrib>Porcheron, Marion</creatorcontrib><creatorcontrib>Martin-Blondel, Guillaume</creatorcontrib><creatorcontrib>Chapuy-Regaud, Sabine</creatorcontrib><creatorcontrib>Izopet, Jacques</creatorcontrib><title>Heterologous ChAdOx1-S/BNT162b2 Vaccination: Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Dear Editor,A recent report questioned whether one vaccine was better than another and how to evaluate this difference, but only homologous vaccination schedules were considered. Concern about the safety of the ChAdOx1-S vaccine have prompted some European countries to recommend using a heterologous booster, as proposed for mRNA vaccines for people under 55 years old . Immunogenicity and reactogenicity of a BNT162b2 booster in ChAdOx1-S-primed subjects was assessed in a multicenter, open-label, randomised, controled phase 2 trial, but included no homologous vaccination comparator. Few studies have compared the immune responses to homologous and heterologous vaccinationschedules in humans.</description><subject>Antibodies, Neutralizing</subject><subject>Antibodies, Viral</subject><subject>BNT162 Vaccine</subject><subject>COVID-19 - prevention & control</subject><subject>Humans</subject><subject>Immunology</subject><subject>Life Sciences</subject><subject>SARS-CoV-2</subject><subject>Vaccination</subject><subject>Vaccinology</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtOwzAQRS0EorxW7JFXCIRCx3bsJuxCBBSpohKBbiPHdopRG1dOUlF-gZ8mpdAli3lo5swd6SJ0SuCaQMz6yuouZDEAvoMOCGeDQPCY7HY98CgIIxb10GFdvwMQEgHfRz0WsojFQA_Q19A0xruZm7q2xulboscfJMj6t08vRNCC4olUylaysa66wU-mbbyc2U9bTXFSNbZweoWfTb1wVW1w43BmlsYbnKi2MT8L62Xj_Apnq0p7Nzc4dd5Vcml994_iiyx5zoLUTQJ6eYz2SjmrzclvPUKv93cv6TAYjR8e02QUKBaTJtAQC1JQASpkTEQ0FpqHWomSk5jLkgqlgJq4YFQaHkYgugxUMgClB7Qs2BG63Oi-yVm-8HYu_Sp30ubDZJSvZ7CWDQlfko692rDKu7r2ptweEMjX9ued_fmv_R19tqEXbTE3esv--d0B5xvAtYt_lb4BKQuM3g</recordid><startdate>20220409</startdate><enddate>20220409</enddate><creator>Dimeglio, Chloé</creator><creator>Herin, Fabrice</creator><creator>Da-Silva, Isabelle</creator><creator>Jougla, Isabelle</creator><creator>Pradere, Claire</creator><creator>Porcheron, Marion</creator><creator>Martin-Blondel, Guillaume</creator><creator>Chapuy-Regaud, Sabine</creator><creator>Izopet, Jacques</creator><general>Oxford University Press</general><general>Oxford University Press (OUP)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-3713-4913</orcidid><orcidid>https://orcid.org/0000-0003-0689-7608</orcidid><orcidid>https://orcid.org/0000-0002-8462-3234</orcidid><orcidid>https://orcid.org/0000-0002-8363-7028</orcidid><orcidid>https://orcid.org/0000-0001-6020-2083</orcidid></search><sort><creationdate>20220409</creationdate><title>Heterologous ChAdOx1-S/BNT162b2 Vaccination: Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)</title><author>Dimeglio, Chloé ; Herin, Fabrice ; Da-Silva, Isabelle ; Jougla, Isabelle ; Pradere, Claire ; Porcheron, Marion ; Martin-Blondel, Guillaume ; Chapuy-Regaud, Sabine ; Izopet, Jacques</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-d0961b260c43368296d54dc6f5195af26cc02e9b32ae54806e5402a300cd72fb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antibodies, Neutralizing</topic><topic>Antibodies, Viral</topic><topic>BNT162 Vaccine</topic><topic>COVID-19 - prevention & control</topic><topic>Humans</topic><topic>Immunology</topic><topic>Life Sciences</topic><topic>SARS-CoV-2</topic><topic>Vaccination</topic><topic>Vaccinology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dimeglio, Chloé</creatorcontrib><creatorcontrib>Herin, Fabrice</creatorcontrib><creatorcontrib>Da-Silva, Isabelle</creatorcontrib><creatorcontrib>Jougla, Isabelle</creatorcontrib><creatorcontrib>Pradere, Claire</creatorcontrib><creatorcontrib>Porcheron, Marion</creatorcontrib><creatorcontrib>Martin-Blondel, Guillaume</creatorcontrib><creatorcontrib>Chapuy-Regaud, Sabine</creatorcontrib><creatorcontrib>Izopet, Jacques</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dimeglio, Chloé</au><au>Herin, Fabrice</au><au>Da-Silva, Isabelle</au><au>Jougla, Isabelle</au><au>Pradere, Claire</au><au>Porcheron, Marion</au><au>Martin-Blondel, Guillaume</au><au>Chapuy-Regaud, Sabine</au><au>Izopet, Jacques</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Heterologous ChAdOx1-S/BNT162b2 Vaccination: Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2022-04-09</date><risdate>2022</risdate><volume>74</volume><issue>7</issue><spage>1315</spage><epage>1316</epage><pages>1315-1316</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Dear Editor,A recent report questioned whether one vaccine was better than another and how to evaluate this difference, but only homologous vaccination schedules were considered. Concern about the safety of the ChAdOx1-S vaccine have prompted some European countries to recommend using a heterologous booster, as proposed for mRNA vaccines for people under 55 years old . Immunogenicity and reactogenicity of a BNT162b2 booster in ChAdOx1-S-primed subjects was assessed in a multicenter, open-label, randomised, controled phase 2 trial, but included no homologous vaccination comparator. Few studies have compared the immune responses to homologous and heterologous vaccinationschedules in humans.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>34383902</pmid><doi>10.1093/cid/ciab705</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0002-3713-4913</orcidid><orcidid>https://orcid.org/0000-0003-0689-7608</orcidid><orcidid>https://orcid.org/0000-0002-8462-3234</orcidid><orcidid>https://orcid.org/0000-0002-8363-7028</orcidid><orcidid>https://orcid.org/0000-0001-6020-2083</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2022-04, Vol.74 (7), p.1315-1316 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_03682415v1 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Antibodies, Neutralizing Antibodies, Viral BNT162 Vaccine COVID-19 - prevention & control Humans Immunology Life Sciences SARS-CoV-2 Vaccination Vaccinology |
| title | Heterologous ChAdOx1-S/BNT162b2 Vaccination: Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T20%3A36%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Heterologous%20ChAdOx1-S/BNT162b2%20Vaccination:%20Neutralizing%20Antibody%20Response%20to%20Severe%20Acute%20Respiratory%20Syndrome%20Coronavirus%202%20(SARS-CoV-2)&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Dimeglio,%20Chlo%C3%A9&rft.date=2022-04-09&rft.volume=74&rft.issue=7&rft.spage=1315&rft.epage=1316&rft.pages=1315-1316&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/ciab705&rft_dat=%3Coup_hal_p%3E10.1093/cid/ciab705%3C/oup_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/34383902&rft_oup_id=10.1093/cid/ciab705&rfr_iscdi=true |